Recherches "plusieurs pathologies" DERMACLIC (IC 2019-12) Study on skin toxicities induced by cancer treatments Paris
Pédiatrie Tumeurs solides LYNPARZA (D0816C000025) A Phase I, Open-label, Parallel Group Study to Investigate Olaparib Safety;and Tolerability, Efficacy and Pharmacokinetics in Paediatric Patients with;Solid Tumours Paris ISABELLE AERTS
Recherches "plusieurs pathologies" MCLA-128-CL01 A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion Saint-Cloud
Pédiatrie Tumeurs solides MUCILA Multicenter double blind randomized placebo-controlled trial assessing the efficacy of low-level laser therapy in the prevention of chemotherapy-induced mucositis in children and young adults treated for a tumoral disease. Paris
Sarcomes STRASS 2 - ETUDE 1809-STBSG A randomized phase III study of neoadjuvant chemotherapy;followed by surgery versus surgery alone for patients with;High Risk RetroPeritoneal Sarcoma (STRASS 2) Paris SYLVIE BONVALOT
Pédiatrie Tumeurs solides INFORM2 - NIVENT (IC 2018-07) INFORM2 Exploratory Multinational Phase I/II Combination Study of Nivolumab and Entinostat in Children and Adolescents With Refractory High-risk Malignancies Paris GUDRUN SCHLEIERMACHER
Appareil Digestif PERSPECTIVE (MS202202-0002) A Phase II Single-Arm Study to Investigate Tepotinib Combined With Cetuximab in RAS/BRAF Wild-Type Left-Sided mCRC Patients Having Acquired Resistance to Anti-EGFR Antibody Targeting Therapy Due to MET Amplification (PERSPECTIVE) Saint-Cloud
Recherches "plusieurs pathologies" EPITOP 01 Elderly Cancer PatIents Treated for Advanced or Metastatic Melanoma or NSCLC, Safety and qualiTy of Life Under immunOtheraPies: a Phase IV Trial Saint-Cloud MICHAEL BRINGUIER
Pédiatrie Tumeurs solides GSK213406 A Phase 1, Multicentre, Open-label, Dose-escalation and Cohort Expansion Study of;Niraparib and Dostarlimab in Paediatric Patients with Recurrent or Refractory Solid Tumours Paris FRANCOIS DOZ
Recherches "plusieurs pathologies" NANORAD2 Radiotherapy of Multiple Brain Metastases Using AGuIX® Gadolinium-chelated Polysiloxane Based Nanoparticles: a Prospective Randomized Phase II Clinical Trial. Saint-Cloud JOELLE OTZ